Those who are currently looking into the pharmaceutical sector for potential investments could consider taking a look at the RespireRx Pharmaceuticals Inc (OTCMKTS:RSPI) stock.
Trading Data
On Monday, RSPI stock jumped 3.27% to $0.0158 with more than 80k shares, compared to its average volume of 360K shares. The stock has moved within a range of $0.0100 – 0.0159 after opening trade at $0.0120.
Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81
The stock has made a strong move over the course of the past few days and the trend continued on Monday as the RespireRx stock ended the day with gains of 3%. That took its cumulative gains over the course of the past week to as much as 11%. The company is involved in developing advanced and innovative treatment that are supposed to tackle diseases that are brought about by problems in neuronal signalling.
Yesterday, the company was back in focus among investors after it announced that its scientists had published an article in the journal Pharmacology and Therapeutics. It is a peer reviewed journal and the article is titled “GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors”.
The publication in a peer reviewed journal is a significant achievement for any company and hence, the rally in the stock on Monday was not particularly surprising. At this point in time, it may be a good idea for investors to add RespireRx to their watch lists.
Technical Data
RSPI stock is trading in the neutral zone as RSI stands at 44. The stock has pivot supports at 0.0060, 0.0080, 0.0119 and resistances at 0.0178, 0.0198, 0.0237. The stock is down 32% in the past month.
